Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: Comparison of DPP-4 inhibitors with other oral antidiabetic drugs

Diabetes, Obesity and Metabolism

Volumn 17, Issue 4, 2015, Pages 430-434

  Yabe, D ^a,b   Kuwata, H ^a   Kaneko, M ^c   Ito, C ^c   Nishikino, R ^c   Murorani, K ^d   Kurose, T ^a   Seino, Y ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Japan Medical Data Center   (Japan)

^d NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute pancreatitis; Claims database; Dipeptidyl peptidase 4 inhibitor

Indexed keywords

BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSIDASE INHIBITOR; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; ANTIDIABETIC AGENT;

ACUTE PANCREATITIS; ADULT; AGED; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; JAPANESE (PEOPLE); LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCRIPTION; REFERENCE DATABASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FACTUAL DATABASE; IMMUNOLOGY; JAPAN; ORAL DRUG ADMINISTRATION; PANCREAS; PANCREATITIS; RISK; SURVIVAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PANCREAS; PANCREATITIS; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS;

EID: 84924749647     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12381     Document Type: Letter

References (11)

1. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother 2013; 14: 2047-2058.
2. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and Non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696-708.
3. Seino Y, Yabe D. GIP and GLP-1: incretin actions beyond pancreas. J Diabetes Invest 2013; 4: 108-130.
4. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66(Suppl 1): S37-44.
5. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013; 36: 2126-2132.
6. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013; 36: 2118-2125.
7. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014; 370: 794-797.
8. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
9. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
10. Takada T (ed). JPN guidelines for the management of acute pancreatitis. In: JPN Guidelines 2010. 3rd edn. Tokyo: Kanehara, 2009; 22-23.
11. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834-838.